2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2564

Autophagy Alteration Affects Migration and Proliferation of Rheumatoid Arthritis Fibroblast-like Synoviocytes Stimulated By IL-17A
Abstract Number: 2565

Common Biomarker Elevations in Idiopathic Pulmonary Fibrosis and Rheumatoid Arthritis-Associated Interstitial Lung Disease
Abstract Number: 2566

Hexokinase 2 As a Novel Metabolic Target for Rheumatoid Arthritis
Abstract Number: 2567

The Effect of Fibroblast Growth Factor 4 on the Proliferation of Fibroblast-like Synoviocytes in Rheumatoid Arthritis
Abstract Number: 2568

ARL15 expressed By Rheumatoid Arthritis Synovial Fibroblasts Regulates IL6 and Plays a Role in Apoptosis and Hypoxia
Abstract Number: 2569

Restoration of Decreased Lymphocyte Counts and the Shift to Th1 and Effector Memory CD8+T Cell Subsets Associate with Spontaneous Regression of Lympho-Proliferative Disorders Developed in RA Patients Treated with Methotrexate
Abstract Number: 2570

Pyruvate Regulates Reactive Oxygen Species (ROS) Production, Dysfunction and Aberrant Metabolism of Mitochondria in Fibroblast-like Synoviocytes of Rheumatoid Arthritis
Abstract Number: 2571

Distinct Oral and Fecal Community Profiles Enriched in Opportunistic Pathogens in RA Patients and First Degree Relatives Are Influenced By Environmental Risk Factors, Including Smoking, Dental History and Lung Infection
Abstract Number: 2572

Study of Two Biomarkers of Biological Age in the Blood of Patients with Rheumatoid Arthritis
Abstract Number: 2573

Galectin 1 As Potential Prognostic Biomarker in Rheumatoid Arthritis
Abstract Number: 2574

IL-22 As a Biomarker for Erosive Disease in Rheumatoid Arthritis
Abstract Number: 2575

The Presence of Staphylococcal Toxins in the Urine of Patients with Rheumatoid Arthritis
Abstract Number: 2576

uPAR Promotes Tumor-like Biologic Role of Fibroblast-like Synoviocytes through PI3K/Akt Signaling Pathway in Patients with Rheumatoid Arthritis
Abstract Number: 2577

Elevated Matrix Metalloproteinases Levels in Oral Fluids of Most Rheumatoid Arthritis Patients, Even without Frank Periodontitis
Abstract Number: 2578

Plasma Levels of Bone Morphogenetic Protein (BMP) Subgroups and Their Inhibitors (noggin, sclerostin) in Rheumatoid Arthritis Patients and Correlation with Disease Activity, Clinical and Radiographic Progression

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].